Skip to main content
Smart Investors Daily
AP

NASDAQ · APEN

Apollo Endosurgery, Inc.

Healthcare · Medical - Devices

$10.00

Up+$0.00 (+0.00%)

Updated Sep 17, 2026, 12:14 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
579.72M
P/E ratio
-10.2
Dividend yield
0.00%
52-week range
— – —
Volume
1.64M
Avg. volume
1.33M

Price performance

APEN price history

1M range · 0 trading sessions · Daily adjusted prices

APEN does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest APEN news

The latest Smart Investors Daily articles mentioning APEN.

APEN research

Overview

Company profile and research snapshot.

Company profile

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
$9.50
Implied upside
Analysts
APEN recent ratings
DateFirmRatingTarget
Jan 23, 2023Cowen & Co.Market Perform
Jan 4, 2023StifelHold
Nov 30, 2022Lake StreetHold
May 4, 2022Stephens & Co.Overweight
Feb 23, 2022StifelBuy
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Jan 3, 2023

10 Best Stock Traders In Congress In 2022 (Spoiler: Nancy Pelosi Isn't No. 1)

A new report was out about the performance of members of the U.S. Congress who bought and sold stocks and options in 2022. The report broke down unusual trading activity from members of Congress and also showed the members who beat the returns of the S&P 500. Here are the highlights of the report. What Happened: The year 2022 was the worst for the S&P 500, as tracked by the SPDR S&P 500 ETF Trust (NYSE: SPY), since 2008. Despite the bad returns for the overall market, 26 members of Congress beat the S&P 500 with their 2022 return, according to a new detailed report from Unusual Whales. In 2022, 131 members of Congress filed stock and options trading disclosures. This figure was down from 147 members in 2021. The report tracked $788 million in trades from more than 12,700 transactions. The number of transactions was similar to 2021, with around $189 million less traded in 2022 than the previous year. The report found House Republicans had more than 1,000 fewer trades in 2022. House Democrats had over 1,000 more trades in 2022 compared to the previous year. Democrats saw an average return of -1.76% and Republicans saw an average return of 0.4%, both beating the -18% return of the S&P 500 in 2022. Over the past 10 years, about 10% of fund managers outperformed the S&P 500, according to SPIVA data, while in 2022, about 5% of total Congress outperformed. When just comparing the Congressional members who traded — just 131 of the possible 535 — 26 beat the market. That equates to 20%, a much higher rate than professional money managers over time. Here were the top 10 members of Congress by 2022 return, according to the report: Rep. ...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.